tirzepatide glp1 and gip New Weight-Loss Drugs Are Poised to Upend Preventive Cardiology Care in Patients With Obesity and Overweight

Semaglutide and #tirzepatide effectively target #GLP1 and GIP receptors for obesity treatment, with future therapies exploring further receptor targeting for improved outcomes. https://ja.ma/4oHQi4J

23.34

★★★★☆4.8 (126)

The importance of glucose‐dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide - Gasbjerg - 2023 - Diabetes, Obesity and Metabolism

29.44

★★★★★4.9 (98)

Sweet Temptation, bitter Truth: Diabetes in the Research Spotlight

24.55

★★★★★5.0 (157)

Tirzepatide (LY3298176) is a Dual GIP and GLP-1 Receptor Agonist for Type 2 Diabetes Research

24.45

★★★★★4.7 (84)

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction | Cardiovascular Diabetology

28.84

★★★★★4.9 (203)

Tirzepatide is redefining obesity & diabetes care. Dual GIP/GLP-1 action → deeper weight loss, stronger metabolic control, and emerging benefits from OSA to cardiometabolic risk. The era of multi-pathway incretin therapy has

25.04

★★★★★5.0 (176)

Tirzepatide is a first-in-class dual agonist targeting both GIP and GLP-1 receptors, offering a powerful and synergistic approach to glycaemic control and weight management., By acting on multiple

24.36

★★★★★4.8 (132)